Table 2.
|
Demographic character |
|
Methodological character |
|
|
||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study |
|
ASD group |
TD group |
|
Value |
ROI tract |
|||||||||||||||||||||||
Na | Males | Mean age (years) | IQb | Nc | Males | Mean age (years) | IQb | Diagnostic tools | Medication / comorbidity | Tesla | B factor | Number of direction | NEX | TE/TR (ms) | Type of WBA | FA | MD | RD | AD | ADC | CC | UF | Cg | SLF | ILF | IFOF | Fo | AF | |
Whole brain voxel-wise analysis study | |||||||||||||||||||||||||||||
Alexander and colleagues [24] |
43 |
43 |
16.2 |
107 |
34 |
34 |
16.4 |
113 |
DSM-IV/ICD-10/ADI-R/ADOS-G |
Yes/Yes |
3 |
1,000 |
12 |
4 |
84/7,000 |
ROI |
○ |
○ |
○ |
○ |
× |
○ |
× |
× |
× |
× |
× |
× |
× |
Ameis and colleagues [43] |
19 |
16 |
12.4 |
98.5 |
16 |
8 |
12.3 |
101 |
DSM-IV/ADI-R/ADOS |
No/No |
3 |
1,250 |
12 |
5 |
80/4,100 |
ROI |
○ |
○ |
× |
× |
× |
○ |
× |
○ |
○ |
× |
× |
× |
× |
Beacher and colleagues [58] |
28 |
15 |
32 |
NA |
30 |
15 |
30 |
NA |
DSM-IV |
Yes/No |
1.5 |
1,000 |
64 |
NA |
95/8,000 |
ROI |
○ |
× |
× |
× |
× |
○ |
× |
× |
× |
× |
× |
× |
× |
Ben Bashat and colleagues [64] |
17 |
NA |
NA |
NA |
NA |
NA |
9.6 |
NA |
DSM-IV/ADI-R/ADOS |
NA/NA |
1.5 |
6,000 |
6 |
4 |
128/1,800 |
ROI |
○ |
○ |
× |
× |
× |
○ |
× |
○ |
○ |
× |
× |
× |
× |
Brito and colleagues [32] |
8 |
8 |
9.53 |
NA |
8 |
8 |
9.57 |
NA |
DSM-IV |
Yes/No |
1.5 |
100 |
12 |
3 |
90/3,100 |
|
○ |
× |
× |
× |
× |
○ |
× |
× |
× |
× |
× |
× |
× |
Catani and colleagues [67] |
15 |
15 |
31 |
109 |
16 |
16 |
35 |
120 |
ICD-10/ADI/ADOS |
NA/No |
1.5 |
1,300 |
64 |
NA |
107/1,500 |
Tractography |
○ |
○ |
× |
× |
× |
○ |
× |
○ |
× |
○ |
× |
× |
× |
Cheon and colleagues [62] |
17 |
17 |
11 |
112 |
17 |
17 |
10.2 |
114 |
DSM-IV/ ADI-R/ADOS |
Yes/No |
1.5 |
900 |
30 |
2 |
86/6500 |
ROI |
○ |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
Conturo and colleagues [74] |
17 |
14 |
26.5 |
104 |
17 |
14 |
26.1 |
105 |
ADI-R/ADOS |
Yes/No |
1.5 |
NA |
7 |
10 |
94/1,51750 |
Tractography |
○ |
○ |
○ |
○ |
× |
○ |
○ |
× |
× |
○ |
× |
× |
× |
Fletcher and colleagues [59] |
10 |
10 |
14.3 |
106 |
10 |
10 |
13.4 |
108 |
DSM-IV/ICD-10/ADI-R/ADOS |
NA/NA |
3 |
1,000 |
12 |
4 |
84/700 |
ROI |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
Hong and colleagues [60] |
18 |
18 |
8.69 |
105 |
16 |
16 |
9.81 |
106 |
DSM-IV/ADI-R |
No/No |
1.5 |
1,000 |
15 |
2 |
104.4/8,000 |
ROI |
○ |
× |
× |
× |
○ |
○ |
× |
× |
× |
× |
× |
× |
× |
Ingalhalikar and colleagues [69] |
45 |
42 |
10.5 |
NA |
30 |
14 |
10.3 |
NA |
NA |
NA/NA |
3 |
1,000 |
15 |
NA |
70/16,900 |
ROI |
○ |
× |
× |
× |
× |
× |
× |
× |
○ |
× |
× |
× |
× |
Knaus and colleagues [66] |
14 |
14 |
16.1 |
103 |
20 |
20 |
14.1 |
116 |
DSM-IV/ADI-ADOS |
NA/No |
3 |
1,000 |
15 |
NA |
N/A |
Tractography |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
○ |
Kumar and colleagues [26] |
32 |
29 |
5 |
NA |
16 |
12 |
5.5 |
Na |
DSM-IV |
NA/No |
3 |
1,000 |
6 |
6 |
79/10,000 |
Tractography |
○ |
× |
× |
× |
○ |
○ |
○ |
○ |
× |
× |
○ |
× |
○ |
Langen and colleagues [73] |
21 |
21 |
25.6 |
107 |
22 |
22 |
28.5 |
110 |
ICD-10/ADI-R/ADOS |
No/No |
3 |
1,300 |
32 |
NA |
107/10,000 |
Tractography |
○ |
○ |
○ |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
× |
Leemans and Jones [78] |
43 |
43 |
16.2 |
108 |
34 |
34 |
16.4 |
113 |
DSM-IV/ICD-10/ADI-R/ADOS-G |
NA/No |
3 |
1,000 |
12 |
3 |
84/7,000 |
ROI |
○ |
○ |
○ |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
× |
Lo and colleagues [25] |
15 |
15 |
15.2 |
108 |
15 |
NA |
15 |
111 |
DSM-IV/ICD-10/ADI-R |
NA/No |
3 |
6,000/4,000 |
102 |
NA |
142/9,100, 130/9,600 |
ROI |
○ |
× |
× |
× |
× |
○ |
○ |
○ |
× |
× |
× |
× |
○ |
Poustka and colleagues [63] |
18 |
16 |
19.7 |
111 |
18 |
16 |
9.7 |
113 |
ICD-10/ADI/ADOS |
NA/No |
1.5 |
1,000 |
6 |
15 |
78/4,700 |
ROI |
○ |
× |
× |
× |
× |
○ |
○ |
× |
○ |
× |
× |
○ |
× |
Pugliese and colleagues [57] |
24 |
24 |
23.3 |
105 |
24 |
24 |
25.3 |
121 |
ICD-10/ADI-R |
No/No |
NA |
1,300 |
32 |
NA |
107/15,000 |
Tractography |
○ |
○ |
× |
× |
× |
× |
○ |
○ |
× |
○ |
○ |
○ |
× |
Sahyoun and colleagues [71] |
9 |
7 |
12.8 |
101 |
12 |
9 |
13.3 |
106 |
ADIM-IV/ADI-R |
No/No |
3 |
700 |
60 |
Na |
84/7,980 |
ROI |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
Shukla and colleagues [65] |
24 |
24 |
5 |
NA |
16 |
12 |
5.9 |
NA |
ADI-R/ADOS |
Yes/No |
3 |
200 |
15 |
4 |
99.4/1,0000 |
ROI |
|
○ |
○ |
○ |
× |
○ |
× |
× |
× |
× |
× |
× |
× |
Sivaswamy and colleagues [68] |
27 |
24 |
5 |
NA |
16 |
12 |
5.9 |
NA |
DSM-IV |
Yes/No |
3 |
1,000 |
6 |
6 |
160/11000 |
ROI |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
× |
Sundaram and colleagues [72] |
50 |
43 |
4.79 |
NA |
16 |
11 |
6.84 |
NA |
DSM-IV0 |
Yes/No |
3 |
1,000 |
6 |
6 |
79/10,000 |
Tractography |
○ |
× |
× |
× |
○ |
× |
× |
× |
× |
× |
× |
× |
× |
Thomas and colleagues [28] |
12 |
12 |
28.5 |
107 |
18 |
18 |
22.4 |
112 |
DSM-IV/ ADI-R/ADOS |
NA/No |
3 |
850 |
6 |
12 |
82/4,900 |
ROI |
○ |
× |
× |
× |
× |
× |
○ |
× |
× |
○ |
○ |
× |
× |
Verhoeven and colleagues [61] |
19 |
16 |
13.8 |
NA |
33 |
24 |
12.9 |
NA |
DSM-IV |
Yes/No |
3 |
800 |
45 |
2 |
55/11,043 |
Tractography |
○ |
× |
× |
× |
○ |
× |
× |
× |
○ |
× |
× |
× |
× |
Weinstein and colleagues [27] | 22 | NA | 3.2 | NA | 28 | NA | 3.6 | NA | DSM-IV ADI-R/ADOS | NA/Yes | 1.5 | 1,000 | 15 | 2 | 94/11,043 | Tractography | ○ | ○ | ○ | ○ | × | ○ | × | ○ | ○ | × | × | × | × |
aNumber of ASD participants. bMean IQ of participants. cNumber of controls. AD axial diffusivity, ADC apparent diffusion coefficient, ADIR Autism Diagnostic Interview-Revised, ADOS Autism Diagnostic Observation Schedule, AF arcuate fasciculus, ASD autism spectrum disorder, CC corpus callosum, Cg cingulum, DSM-IV Diagnostic and Statistical Manual of Mental Disorders-IV, FA fractional anisotropy, Fo fornix, ICD-10 International Statistical Classification of Diseases and Related Health Problems-10, IFOF inferior frontal occipital fasciculus, ILF inferior longitudinal fasciculus, MD mean diffusivity, NA not available, NEX number of excitation, RD radial diffusivity, ROI region of interest, SLF superior longitudinal fasciculus, TD typically developing, TE echo time, TR repetition time, UF uncinate fasculus.